THZ531，25MG，SML2619-25MG，Sigma

Biochem/physiol Actions

Potent and selective cyclin-dependent kinase CDK12/13 inhibitor that targets CDK12 Cys1039 and CDK13 Cys1017 for irreversible covalent modification.
THZ531 is a potent, CDK12/13-selective cyclin-dependent kinase inhibitor (IC50 = 158 nM, 69 nM, 10.5 μM, respectively, against 0.2 ?M CDK12-CycK, CDK13-CycK, CDK9-CycT1; IC50 = 8.5 μM against 25 nM CDK7-CycH-MAT1) that targets CDK12 Cys1039 and CDK13 Cys1017 for irreversible covalent modification while bound to the ATP-binding site, displaying good selectivity over >200 other kinases. THZ531 selectively reduces Pol II CTD Ser2, but not Ser5/Ser7, phosphorylation and transcription activity in Jurkat cultures (200-500 nM), exhibiting antiproliferation potency (IC50 = 50 nM in 72 h) due to time- and dose-dependent apoptosis induction.